LUXIQ Drug Patent Profile

Which patents cover Luxiq, and what generic alternatives are available?

Luxiq is a drug marketed by Norvium Bioscience and is included in one NDA.

The generic ingredient in LUXIQ is betamethasone valerate. There are sixty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the betamethasone valerate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Luxiq

A generic version of LUXIQ was approved as betamethasone valerate by FOUGERA PHARMS INC on August 31^st, 1983.

Summary for LUXIQ

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	4,746
Drug Prices:	Drug price information for LUXIQ
What excipients (inactive ingredients) are in LUXIQ?	LUXIQ excipients list
DailyMed Link:	LUXIQ at DailyMed

See drug prices for LUXIQ

Paragraph IV (Patent) Challenges for LUXIQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUXIQ	Foam	betamethasone valerate	0.12%	020934	1	2007-08-10

US Patents and Regulatory Information for LUXIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999		DISCN	Yes	No

Expired US Patents for LUXIQ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999
Norvium Bioscience	LUXIQ	betamethasone valerate	AEROSOL, FOAM;TOPICAL	020934-001	Feb 28, 1999

International Patents for LUXIQ

See the table below for patents covering LUXIQ around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0813413	MOUSSE CONTENANT UN CORTICOSTEROIDE (CORTICOSTEROID-CONTAINING FOAM)
Brazil	9607687
Japan	4557310
Denmark	0813413

LUXIQ Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Drug: LUXIQ

Introduction

LUXIQ, a brand name for betamethasone valerate, is a topical corticosteroid used to treat various dermatological conditions such as atopic dermatitis, psoriasis, and other skin disorders. Here, we will delve into the market dynamics and financial trajectory of LUXIQ, including its availability, pricing, and the broader market context.

Availability and Formulations

LUXIQ was approved by the FDA on February 28, 1999, and is available in a topical foam formulation with a strength of 0.12% betamethasone valerate. However, all formulations of LUXIQ have been discontinued, which significantly impacts its market presence and availability[1].

Pricing and Cost

The cost of LUXIQ, prior to its discontinuation, was substantial. For a supply of 50 grams of the 0.12% topical foam, the price was around $202 for cash-paying customers. This pricing is based on the use of discount cards and can vary depending on the pharmacy[2].

Generic Availability

Although the brand name LUXIQ is no longer available, a generic version of betamethasone valerate is accessible. The generic prices are more affordable, starting from $113.25 for a 50-gram supply, making it a more cost-effective option for patients[2].

Market Impact of Discontinuation

The discontinuation of LUXIQ formulations has a significant impact on the market. Patients who were using LUXIQ may need to switch to alternative treatments, including generic versions or other topical corticosteroids. This shift can influence market dynamics, as patients and healthcare providers seek out replacement therapies.

Safety and Efficacy

LUXIQ has been studied for its safety and efficacy in clinical trials. The most common adverse reactions include local skin reactions such as burning, stinging, and itching, which are generally mild to moderate. There was no significant suppression of the hypothalamic-pituitary-adrenal (HPA) axis in studies involving patients with psoriasis or atopic dermatitis[4].

Regulatory and Safety Considerations

It is crucial for patients and healthcare providers to be aware of the potential risks associated with topical corticosteroids, including HPA axis suppression. Patients treated over large body surface areas should be monitored periodically for signs of HPA axis suppression, and the drug should be withdrawn gradually if suppression is noted[4].

Financial Trajectory

The financial trajectory of LUXIQ is heavily influenced by its discontinuation. Without ongoing sales, the revenue generated from LUXIQ has ceased. However, the broader market for topical corticosteroids remains robust, driven by the demand for treatments for dermatological conditions.

Broader Market Context

The dermatology market, in which LUXIQ operates, is significant and growing. Companies like Stiefel Laboratories, which was a major player in dermatology before its acquisition, have demonstrated strong growth trajectories through product development, licensing, and acquisitions. For instance, Stiefel Laboratories received a $500 million minority investment from The Blackstone Group in 2007 to accelerate its growth in the dermatology sector[5].

Competitive Landscape

The discontinuation of LUXIQ opens up market space for other topical corticosteroids and generic alternatives. Companies that offer these alternatives can capitalize on the demand for effective dermatological treatments. The competitive landscape is dynamic, with companies continually developing new products and technologies to meet patient needs.

Patient Assistance and Discounts

For patients transitioning from LUXIQ to other treatments, discount programs and patient assistance plans can be crucial. Programs like the Drugs.com Discount Card can help reduce the cost of prescription medications, making them more accessible to patients[2].

Conclusion

The market dynamics and financial trajectory of LUXIQ are marked by its discontinuation, which has significant implications for both patients and the broader dermatology market. While LUXIQ is no longer available, the demand for effective topical corticosteroids remains high, driving the market forward.

Key Takeaways

• Discontinuation: All formulations of LUXIQ have been discontinued.
• Pricing: The cost of LUXIQ was around $202 for a 50-gram supply before its discontinuation.
• Generic Availability: Generic versions of betamethasone valerate are available and more affordable.
• Safety and Efficacy: LUXIQ has been shown to be effective with mild to moderate adverse reactions.
• Regulatory Considerations: Patients should be monitored for HPA axis suppression.
• Financial Trajectory: Revenue from LUXIQ has ceased due to its discontinuation.
• Broader Market Context: The dermatology market remains robust with growing demand.

FAQs

1. What is LUXIQ used for? LUXIQ is used to treat various dermatological conditions such as atopic dermatitis, psoriasis, and other skin disorders.

2. Why is LUXIQ no longer available? All formulations of LUXIQ have been discontinued, although the exact reasons are not specified.

3. What are the common adverse reactions to LUXIQ? Common adverse reactions include local skin reactions such as burning, stinging, and itching, which are generally mild to moderate[4].

4. Can I still get a generic version of LUXIQ? Yes, a generic version of betamethasone valerate is available and more affordable than the brand name[2].

5. How can patients reduce the cost of alternative treatments? Patients can use discount programs like the Drugs.com Discount Card to reduce the cost of prescription medications[2].

Sources

1. Generic Luxiq Availability - Drugs.com
2. Luxiq Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. A Multi-Billion-Dollar Drug Market | Baron Funds
4. LUXIQ - betamethasone valerate Foam, 0.12% w/w Topical - Health Canada
5. Stiefel Laboratories Will Enter Into Private Equity Minority Investment Agreement With The Blackstone Group - Blackstone